The therapeutic potential of MEK inhibition needs to be examined in clinical trials with T2D patients, and further study is needed to explore the exact mechanisms through which inhibiting the MEK1 signaling pathway improves IR, especially in the liver, in order to avoid undesirable adverse events by MEK inhibition [37, 38]. Here, MAP2K1 is linked to type 2 diabetes mellitus.